共 40 条
[1]
Siegel R(2013)Cancer statistics 2013 CA Cancer J Clin 63 11-30
[2]
Naishadham D(2011)New driver mutations in non-small-cell lung cancer Lancet Oncol 12 175-180
[3]
Jemal A(2007)Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large cell lymphoma Mol Cancer Ther 6 3314-3322
[4]
Pao W(2012)Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol 13 1011-1019
[5]
Girard N(2013)Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 23-94
[6]
Christensen JG(2011)Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Lancet Oncol 12 1004-1012
[7]
Zou HY(2008)Practical guidelines for diagnosis and early management of drug-induced liver injury World J Gastroenterol 14 6774-6785
[8]
Arango ME(2009)Epidemiology of idiosyncratic drug-induced liver injury Semin Liver Dis 29 337-347
[9]
Li Q(2012)Crizotinib: in locally advanced or metastatic non-small cell lung cancer Drugs 72 99-107
[10]
Lee JH(2017)Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of Alectinib in ALK-positive non-small cell lung cancer J Thorac Oncol 12 1552-undefined